Invesco Dynamic Biotechnology & Genome ETF (PBE)
|Day's Range||66.00 - 66.77|
|Inception Date||Jun 23, 2005|
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Top 10 Holdings44.29% of assets
|Mar 23, 2020||$0.02898||Mar 31, 2020|
|Sep 24, 2018||$0.00207||Sep 28, 2018|
|Jun 16, 2017||$0.21532||Jun 30, 2017|
|Mar 17, 2017||$0.05552||Mar 31, 2017|
|Dec 16, 2016||$0.1208||Dec 30, 2016|
|Sep 16, 2016||$0.02834||Sep 30, 2016|
Smart Beta ETF report for PBE
Sector ETF report for PBE
Wall Street was downbeat last week with all indexes in the red. Still, Healthcare sector emerged as a key winner last week.
As the stock market attempts to reverse the recent pullback this month, Moderna shares climbed higher on Thursday after the company announced that it's creating a dual-purpose vaccine booster shot that ...
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...
Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...
The approval for Biogen's Alzheimer's disease treatment has spread strong optimism, with many investors pulling in capital to this high growth and high beta sector.
The coronavirus pandemic could be a long-term positive for biopharma companies and the Invesco Dynamic Biotechnology & Genome ETF (PBE). PBE tracks the Dynamic Biotech & Genome Intellidex Index, which “...
The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...
Sector ETF report for PBE
With Regeneron Pharmaceuticals and Eli Lilly & Company requesting the FDA for an Emergency Use Authorization for their antibody therapy treatments, the biotech space is filled with optimism.
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.